Market Overview

UPDATE: Brinson Patrick Initiates Vical at Market Outperform on Allovectin Potential

Related VICL
18 Biggest Mid-Day Gainers For Wednesday
25 Stocks Moving In Wednesday's Pre-Market Session

In a report published Monday, Brinson Patrick analyst Vernon Bernardino initiated coverage on Vical (NASDAQ: VICL) with a Market Outperform rating and $7.00 price target.

In the report, Brinson Patrick noted, “We are initiating coverage of Vical with a Market Outperform rating and 12-month price target of $7. We believe Vical's lead product, Allovectin, is poised to be a significant driver of the company's shares, beginning in 2Q13 with database lock of its Allovectin in metastatic melanoma Phase III trial. We believe the results will be positive, positioning Vical with a blockbuster opportunity in the rapidly evolving melanoma market.”

Vical closed on Friday at $2.93.

Latest Ratings for VICL

Jun 2017Rodman & RenshawAssumesBuy
Jul 2016H.C. WainwrightAssumesBuy
Jun 2015Roth CapitalDowngradesBuyNeutral

View More Analyst Ratings for VICL
View the Latest Analyst Ratings

Posted-In: Brinson Patrick Vernon BernardinoAnalyst Color Initiation Analyst Ratings


Related Articles (VICL)

View Comments and Join the Discussion!